COVID-19 and solid organ transplant outcomes

V. Nair  
*Zucker School of Medicine at Hofstra/Northwell*, vnair5@northwell.edu

N. Jandovitz  
*Northwell Health*

K. D. Jhaveri  
*Zucker School of Medicine at Hofstra/Northwell*, kjhaveri@northwell.edu

E. Molmenti  
*Zucker School of Medicine at Hofstra/Northwell*, emolment@northwell.edu

Follow this and additional works at: [https://academicworks.medicine.hofstra.edu/articles](https://academicworks.medicine.hofstra.edu/articles)

**Recommended Citation**


This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.
COVID-19 and solid organ transplant outcomes

Vinay Nair¹, Nicholas Jandovitz², Kenar D. Jhaveri¹ and Ernesto Molmenti³

¹Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA, ²Department of Pharmacy, North Shore University Hospital, Northwell Health, Manhasset, NY, USA and ³Department of Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA

Correspondence to: Ernesto Molmenti; E-mail emolmenti@northwell.edu

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread out from a single city in China to most of the world. Patients found to be at higher risk for infection and adverse outcome include those with comorbid conditions and the elderly. Until recently, data on immunocompromised kidney transplant patients have been lacking. Given their diminished T-cell immunity, transplant recipients are expected to be at higher risk for severe bacterial and viral infections. This would suggest that they are at higher risk for infection and mortality from coronavirus disease 2019 (COVID-19). However, recent publications report great variations in the clinical course and mortality of COVID-19 in solid organ transplant recipients [1–9].

To better understand the true risk of COVID-19 in transplant recipients, we sought to collect and summarize existing experiences. We performed a PubMed search for all published manuscripts that included kidney transplantation and COVID-19. We excluded studies with fewer than five kidney transplant recipients, and those without data reported. We reviewed dates of publication, number of patients, types of solid organ transplantation including kidney transplantation, patient demographics, comorbid conditions, baseline immunosuppression, changes in immunosuppression, presenting symptoms, hospital course, treatments administered, follow-up time and patient mortality.

Of 13 articles from February to 1 May 2020, 4 were excluded for having fewer than five kidney transplant recipients. A summary of the nine analyzed manuscripts is detailed in Table 1. Two studies [6, 8] included kidney, non-kidney and combined kidney and other organ transplantations. Most studies included patients with a median age in the 50s with primary comorbidities of hypertension and diabetes (in addition to the primary organ failure). The majority of patients were male. COVID-19 diagnosis was confirmed via laboratory testing in all studies. Calcineurin inhibitors, antimetabolites and prednisone were among the types of immunosuppression used. The majority of patients included in the studies were on tacrolimus, mycophenolate and prednisone. The presenting symptoms were usually fever, cough and dyspnea, and less commonly diarrhea. Immunosuppression was either reduced or discontinued upon diagnosis in all studies. Not all authors reported on intensive care unit admission and intubation, potentially introducing a bias in the severity of illness.

All studies published after March 2020 utilized hydroxychloroquine in the majority of COVID-19-positive transplant recipients. Azithromycin, remdesivir, leronlimab, lopinavir/ritonavir, darunavir, oseltamivir and tocilizumab were also used. All studies described hospitalized patients. A third of the reports also included outpatients [3, 6, 7]. The median [interquartile range(IQR)] follow-up time was ~3 weeks for most studies (7–29 days). Mortality ranged from 0% to 30%.

All studies (except Study [1]) that reported patient mortality under 20% did not report follow-up data or reported a median follow-up <10 days. In general, larger studies also tended to have a higher mortality. At the time of our analysis, we observed a higher mortality among more recent reports.

In summary, the available literature suggests that presentation of COVID-19 in transplant recipients is similar among transplant centers around the world. Immunosuppression strategies are also similar and revolve around reducing immunosuppression. Treatment strategies vary; however, all studies utilized some antiviral or anti-inflammatory agent. Differing outcomes may therefore be related to small number of cases, potentially varying acuities of illness, and short (or not reported) follow-up periods being associated with lower mortality. Given that the cytokine storm occurs later in the course of COVID-19, it is plausible that mortality may increase with follow-up. When excluding short or missing follow-up, recent mortality appears to be between 20% and 30%, which suggests that transplant recipients have a higher mortality than the non-immunocompromised population.

It is of utmost importance to understand these risks before proceeding with transplantation in the current era of COVID-19. Factors to be considered include the potential for improved survival and enhanced quality of life, the risk of SARS-CoV-2
<table>
<thead>
<tr>
<th>Studies</th>
<th>Date accepted for publication</th>
<th>Number of patients</th>
<th>Organ transplanted</th>
<th>Age, years</th>
<th>Male gender, %</th>
<th>Time from transplant</th>
<th>Comorbidities, %</th>
<th>Baseline immuno-suppression, %</th>
<th>Presenting symptoms, %</th>
<th>Immuno-suppression reduced/discontinued Treatment(s), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang et al. [1]</td>
<td>March 20</td>
<td>5</td>
<td>Kidney</td>
<td>38 (38–47)</td>
<td>80</td>
<td>352 days (170–929)</td>
<td>HTN 40</td>
<td>Tacrolimus 80</td>
<td>Fever –</td>
<td>HCQ –</td>
</tr>
<tr>
<td>Banerjee et al. [3]</td>
<td>March 27</td>
<td>7</td>
<td>Kidney</td>
<td>54 (45–69)</td>
<td>57</td>
<td>3 to ≥ 1 year</td>
<td>CKD –</td>
<td>MMF/MPA 100</td>
<td>Dyspnea –</td>
<td>Remdesivir –</td>
</tr>
<tr>
<td>Alberici et al. [4]</td>
<td>April 3</td>
<td>20</td>
<td>Kidney</td>
<td>59 (51–64)</td>
<td>80</td>
<td>13 years (9–20)</td>
<td>CHD 20</td>
<td>Prednisone –</td>
<td>Diarrhea –</td>
<td>Tocilizumab –</td>
</tr>
<tr>
<td>Fernandez-Ruiz et al. [6]</td>
<td>April 16</td>
<td>18</td>
<td>Kidney, liver, heart 4</td>
<td>71 (64–75)</td>
<td>77.8</td>
<td>9.3 years (6.3–16.5)</td>
<td>CHD –</td>
<td>Belatacept –</td>
<td>ICU admission 0</td>
<td>Oseltamivir 100</td>
</tr>
<tr>
<td>Akalin et al. [7]</td>
<td>April 24</td>
<td>36</td>
<td>Kidney</td>
<td>60 (32–77)</td>
<td>72</td>
<td>No info</td>
<td>Cirrhosis –</td>
<td>Prednisone –</td>
<td>Intubation/ mechanical ventilation 0</td>
<td>Follow-up, days 29 (27–31)</td>
</tr>
<tr>
<td>Pereira et al. [8]</td>
<td>April 24</td>
<td>90</td>
<td>Kidney, lung, heart 19</td>
<td>57 (46–68)</td>
<td>59</td>
<td>No info</td>
<td>CKD –</td>
<td>HCQ –</td>
<td>Death 0</td>
<td>Oseltamivir 100</td>
</tr>
<tr>
<td>Nair et al. [9]</td>
<td>April 29</td>
<td>10</td>
<td>Kidney</td>
<td>57 (47–67)</td>
<td>60</td>
<td>No info</td>
<td>CHD –</td>
<td>Remdesivir –</td>
<td>Mortality 0</td>
<td>Azithromycin –</td>
</tr>
</tbody>
</table>

*All data presented as median (IQR) unless otherwise noted. CHD: coronary heart disease; CKD: chronic kidney disease; CLD: chronic lung disease; DM: diabetes; ICU: intensive care unit; HCQ: hydroxychloroquine; HTN: hypertension; LPV/r: lopinavir/ritonavir; MMF: mycophenolate mofetil; MPA: mycophenolic acid; mTOR: mammalian target of rapamycin; –, not recorded.
infection in the transplant population when compared with in-center dialysis, and the increased morbidity and mortality associated with COVID-19 in the setting of transplantation. Ongoing studies reporting multi-center data may provide us with more robust information.

CONFLICT OF INTEREST STATEMENT
KDJ is a consultant for Astex pharmaceuticals and Natera. All other authors have no conflict of interests to declare.

REFERENCES

doi: 10.1093/ndt/gfaa202

Oral potassium binders: increasing flexibility in times of crisis

Rakesh Dattani1, Peter Hill1, Nicholas Medjeral-Thomas1,2, Megan E. Griffith1, Damien Ashby1, Stephen McDaid1,2, Richard W. Corbett1, Gaetano Lucisano1, Jack Beadle1, Kieran McCafferty3,*, Andrew Frankel1,*, and David Thomas1,2,*


Correspondence to: Rakesh Dattani; E-mail: rakesh.dattani@nhs.net

*These authors contributed equally to this work.

Successful and safe management of hyperkalaemia became more pertinent during the coronavirus disease 2019 (COVID-19) pandemic, as nephrologists grappled with delayed transfer of patients into renal centres, difficulties providing short-term haemofiltration in intensive care units (ICUs), minimizing hospital visits and reorganizing haemodialysis (HD) services to facilitate isolated COVID-19 areas. With an unprecedented demand, the need to preserve ICU beds, and an often-reduced work force, changes in medical practice were required.

COVID-19 has particularly affected renal patients, with 4360 cases and 1403 deaths in adult renal patients across the UK and Northern Ireland as of 17 June 2020 [1]. Among 1530 HD patients at our centre in North West London, there were 300 cases and 94 deaths [2]. These statistics are unsurprising with COVID-19 risk factors, including advanced age, hypertension, diabetes mellitus and vascular disease, and being of Black, Asian or minority ethnic origin highly prevalent in renal patients.

With a high number of admissions and the need to alter outpatient pathways, renal services were overwhelmed. In an effort to protect patients admitted to non-renal centres and reduce ICU admissions, nephrologists provided remote support to manage serum potassium.

Standard management includes the use of insulin/dextrose, salbutamol and sodium bicarbonate, but their use risks hypoglycaemia, tachyarrhythmias and fluid overload [3, 4]. Newer agents such as sodium zirconium cyclosilicate (SZC), an inorganic crystalline compound, and Patiromer, a cation exchange polymer, are oral, non-absorbed potassium binders, licenced within the UK for acute and chronic hyperkalaemia in adults other than those on renal replacement therapy (RRT) [5]. Furthermore, the Phase IIIb DIALIZE trial showed SZC to be safe in HD patients, with trials under way to determine the efficacy of Patiromer. Their use will therefore increase over time [6, 7].